Related by context. Frequent words. (Click for all words.) 59 Secondary endpoints included 59 plus methotrexate 59 statistically significant p 58 CI -#.# 58 SBMs 57 P = .# 56 mineral density 56 Secondary endpoints include 56 mg BID 56 Postoperative 56 #mg/day [001] 55 virologic response 55 placebo p 55 placebo p = 55 μg kg 55 ACR# response 55 achieved statistical significance 54 plasma glucose 53 fasting plasma glucose 53 serum uric acid 53 mg QD 53 p = #.# [002] 53 constipation diarrhea 53 mucosal healing 53 n = 53 demonstrated statistically significant 53 Tolerability 53 laboratory abnormalities 52 mcg kg 52 symptom severity 52 gout flares 52 hypokalemia 52 statistically significant p = 52 Disease Activity 52 Secondary endpoints 52 inflammatory lesions 52 estimated glomerular filtration 52 glycemia 52 serum concentrations 52 WOMAC 51 ≥ 51 postoperatively 51 annualized relapse 51 DAS# [002] 51 ADAS cog 51 hypoglycemic events 51 log# 51 administered subcutaneously 51 total cholesterol LDL 51 decrements 51 hypocalcemia 51 serum PSA 51 % CI #.#-#.# [003] 51 IPSS 51 tolvaptan 51 fasting insulin 50 certolizumab pegol 50 p = #.# [004] 50 mg kg dose 50 discontinuations due 50 hemoglobin concentration 50 left ventricular systolic 50 dyspnea 50 Main Outcome Measures 50 Preoperative 50 Pharmacokinetic 50 fasting glucose levels 50 Natalizumab 50 sustained virologic response 50 ANOVA 50 peripheral edema 50 LVEF 50 HbA1C 49 ascending doses 49 GERD symptoms 49 fasting blood glucose 49 subcutaneous injections 49 % CI #.#-#.# [007] 49 ml min 49 creatinine clearance 49 preoperatively 49 #mg dose [001] 49 seroprotection 49 Pegasys ® 49 hypomagnesemia 49 orthostatic hypotension 49 mcg dose 49 dose titration 49 HbA 1c 49 IU mL 49 #mg/kg [002] 49 treatment emergent adverse 49 concomitant medications 49 CI #.#-#.# [002] 49 % CI #.#-#.# [006] 49 RLS symptoms 49 intramuscular injections 49 urinary symptoms 49 histopathological 49 Negative Syndrome 49 ULN